Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant

case series and review of the literature

Roberta D'Ambrosio, Alessio Aghemo, Valeria Rossetti, Rosaria Carrinola, Massimo Colombo

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Chronic infection with HCV can rapidly progress to cirrhosis leading to increased mortality rates in immunosuppressed organ-transplanted patients. In liver-transplanted patients, the introduction of directly acting antivirals has modified HCV natural history by providing a safe and effective therapy for this group of patients. To date there are no data on safety and efficacy of IFN-free regimens in HCV patients who received lung transplant (LuT). Methods: We report three patients who have received anti-HCV treatment after LuT with Sofosbuvir-based regimens. Results: All patients achieved a SVR, no unexpected safety signals were observed and no modifications in immunosuppressants were required. Conclusions: Our report is the first to show that HCV patients who underwent LuT can be safely treated with IFN-free regimens, thus opening the door for refined clinical management of this category of patients.

Original languageEnglish
Pages (from-to)1585-1589
Number of pages5
JournalLiver International
Volume36
Issue number11
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Hepacivirus
Transplants
Lung
Therapeutics
Safety
Sofosbuvir
Immunosuppressive Agents
Group Psychotherapy
Natural History
Antiviral Agents
Fibrosis
Mortality
Liver
Infection

Keywords

  • direct acting antivirals
  • hepatitis C virus
  • immunosuppression
  • lung transplant
  • sofosbuvir

ASJC Scopus subject areas

  • Hepatology

Cite this

@article{f52542ccac38455f87fbb5fe177bdcb9,
title = "Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature",
abstract = "Background: Chronic infection with HCV can rapidly progress to cirrhosis leading to increased mortality rates in immunosuppressed organ-transplanted patients. In liver-transplanted patients, the introduction of directly acting antivirals has modified HCV natural history by providing a safe and effective therapy for this group of patients. To date there are no data on safety and efficacy of IFN-free regimens in HCV patients who received lung transplant (LuT). Methods: We report three patients who have received anti-HCV treatment after LuT with Sofosbuvir-based regimens. Results: All patients achieved a SVR, no unexpected safety signals were observed and no modifications in immunosuppressants were required. Conclusions: Our report is the first to show that HCV patients who underwent LuT can be safely treated with IFN-free regimens, thus opening the door for refined clinical management of this category of patients.",
keywords = "direct acting antivirals, hepatitis C virus, immunosuppression, lung transplant, sofosbuvir",
author = "Roberta D'Ambrosio and Alessio Aghemo and Valeria Rossetti and Rosaria Carrinola and Massimo Colombo",
year = "2016",
month = "11",
day = "1",
doi = "10.1111/liv.13203",
language = "English",
volume = "36",
pages = "1585--1589",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "11",

}

TY - JOUR

T1 - Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant

T2 - case series and review of the literature

AU - D'Ambrosio, Roberta

AU - Aghemo, Alessio

AU - Rossetti, Valeria

AU - Carrinola, Rosaria

AU - Colombo, Massimo

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background: Chronic infection with HCV can rapidly progress to cirrhosis leading to increased mortality rates in immunosuppressed organ-transplanted patients. In liver-transplanted patients, the introduction of directly acting antivirals has modified HCV natural history by providing a safe and effective therapy for this group of patients. To date there are no data on safety and efficacy of IFN-free regimens in HCV patients who received lung transplant (LuT). Methods: We report three patients who have received anti-HCV treatment after LuT with Sofosbuvir-based regimens. Results: All patients achieved a SVR, no unexpected safety signals were observed and no modifications in immunosuppressants were required. Conclusions: Our report is the first to show that HCV patients who underwent LuT can be safely treated with IFN-free regimens, thus opening the door for refined clinical management of this category of patients.

AB - Background: Chronic infection with HCV can rapidly progress to cirrhosis leading to increased mortality rates in immunosuppressed organ-transplanted patients. In liver-transplanted patients, the introduction of directly acting antivirals has modified HCV natural history by providing a safe and effective therapy for this group of patients. To date there are no data on safety and efficacy of IFN-free regimens in HCV patients who received lung transplant (LuT). Methods: We report three patients who have received anti-HCV treatment after LuT with Sofosbuvir-based regimens. Results: All patients achieved a SVR, no unexpected safety signals were observed and no modifications in immunosuppressants were required. Conclusions: Our report is the first to show that HCV patients who underwent LuT can be safely treated with IFN-free regimens, thus opening the door for refined clinical management of this category of patients.

KW - direct acting antivirals

KW - hepatitis C virus

KW - immunosuppression

KW - lung transplant

KW - sofosbuvir

UR - http://www.scopus.com/inward/record.url?scp=84991502904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991502904&partnerID=8YFLogxK

U2 - 10.1111/liv.13203

DO - 10.1111/liv.13203

M3 - Article

VL - 36

SP - 1585

EP - 1589

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 11

ER -